Robotic surgery player Medrobotics raises $25M; Neuravi begins enrollment in FDA trial of its stroke-fighting device;

@FierceMedDev: Dx Digest: Illumina launches $250M share repurchase program; Foundation Medicine stumbles with Q3 earnings miss. More | Follow @FierceMedDev

@VarunSaxena2: IYCMI from FierceDrugDelivery: Investigational drug enables faster absorption of bioresorbable drug-eluting stents. Article | Follow @VarunSaxena2

@EmilyWFierce: Medicaid calls on Gilead, AbbVie to answer hep C drug pricing questions. FiercePharma article | Follow @EmilyWFierce

> Stent thrombectomy player Neuravi announced that the first patient has enrolled in the international pivotal trial of its CE-marked EmboTrap device to treat stroke. The study data will form a key plank of the company's submission for FDA approval. More

> Medrobotics announced a $25 million preferred stock financing to support commercialization of the Flex Robotic System for minimally invasive surgery. More

Biotech News

@FierceBiotech: Gilead wins FDA approval for a new HIV combo pill with rivals at its heels. Report | Follow @FierceBiotech

@JohnCFierce: Andy Futreal at MD Anderson is joining my Big Data:2025 panel at . | Follow @JohnCFierce

> AstraZeneca poaches ZS Pharma for $2.7B, beating Actelion to the punch. Report

> Sanofi bets another $1.7B on diabetes to pad its lagging pipeline. Story

> Under Pfizer's gaze, Allergan's Saunders softens his tone on early-stage R&D. Article

Pharma News

@FiercePharma: Australia looks to save cash by cutting scripts for common drugs. FiercePharmaAsia report | Follow @FiercePharma

@EricPFierce: makes sure Denmark gets some of the action as it starts massive build up. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Allergan pumps up its sales rep tally amid Viberzi launch, aesthetics push. FiercePharmaMarketing story | Follow @CarlyHFierce

> Medicaid calls on Gilead, AbbVie to answer hep C drug pricing questions. Report

> Dr. Reddy's feels FDA heat, gets warning letter for three plants. Story

> Sanofi puts 2 units on the block, commits to $1.6B in cuts to turn business around. Article

Suggested Articles

Battelle received an emergency go-ahead from the FDA over the weekend to deploy its decontamination system for N95 respirator masks.

The limited supply of ventilators is one of the chief concerns facing hospitals as they prepare for more COVID-19 cases.

In one of the longest studies to date in high-risk heart disease, researchers found no significant difference in death rates over more than 10 years.